| 查看: 9030 | 回复: 6 | |||
星海慧儿荣誉版主 (职业作家)
木虫精灵
|
[求助]
请教RLD和RS的区别 已有1人参与
|
|
在FDA上看到一个产品有RLD也有RS，但是两者不一个厂家，请教RLD和RS到底有何区别，单从字面讲，似乎RS更令人困惑。 MYLAN的是RS，但不是RLD；ASTRA的在橙皮书检索下是RLD，但在drugs@FDA搜索出来的RLD项下又都是NO，很困惑，求解。  1.png  2.png |
回复此楼» 猜你喜欢
（1055）求药学B区调剂
已经有0人回复
-
责编一直没有给动静 是凉了吗
已经有20人回复
-
药物学论文润色/翻译怎么收费?
已经有123人回复
-
河北医科大学药学相关专业接受调剂
已经有20人回复
-
【招聘】清华大学药学院钱锋教授课题组诚聘博士后
已经有1人回复
-
关于SCI杂志发表挂名
已经有32人回复
-
新版scifinder
已经有1人回复
-
安捷伦液相色谱柱与方法开发指南
已经有4人回复
-
2026申请考核博士自荐-蛋白质组学/AI/药物设计/AIDD/化学生物学
已经有1人回复
mouse103
专家顾问 (著名写手)
- DRDEPI: 16
- 应助: 218 (大学生)
- 贵宾: 0.384
- 金币: 1473.7
- 散金: 2586
- 红花: 171
- 沙发: 1
- 帖子: 1625
- 在线: 411.3小时
- 虫号: 466716
- 注册: 2007-11-24
- 专业: 合成药物化学
- 管辖: 生物医药区
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
感谢参与，应助指数 +1
星海慧儿: 金币+20, ★★★★★最佳答案, 非常感谢！ 2017-02-10 14:57:38
kk1424: 金币+5 2017-02-10 15:24:33
感谢参与，应助指数 +1
星海慧儿: 金币+20, ★★★★★最佳答案, 非常感谢！ 2017-02-10 14:57:38
kk1424: 金币+5 2017-02-10 15:24:33
|
Reference Listed Drug and Reference Standard A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. Generally, a reference listed drug is a drug product approved in a new drug application under section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an in vivo bioequivalence study required for approval. FDA generally selects a single reference standard that ANDA applicants must use in in vivo bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and an ANDA is selected as the reference standard), the reference listed drug and the reference standard may be different. FDA has identified reference listed drugs in the Prescription Drug Product and OTC Drug Product Lists. Forthcoming, FDA will identify reference listed drugs in the Discontinued Drug Product List. These identified reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate. FDA also has identified in the Prescription Drug Product and OTC Drug Product Lists reference standards to which the in vivo bioequivalence is compared. These identified reference standards represent the FDA’s best judgment at this time as to the appropriate comparator for purposes of in vivo bioequivalence testing. In some instances when a listed drug is not designated as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to designate a reference listed drug for that drug product. Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request. If the request is granted, the listed drug will be designated as a reference listed drug, in which case an ANDA citing the designated reference listed drug may be submitted. Section 1.7, Therapeutic Equivalence Evaluations Codes (products meeting necessary bioequivalence requirements) explains the character coding system (e.g., AB, AB1, AB2, AB3...) for multisource drug products listed under the same heading with two reference listed drugs. A potential applicant should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that potential applicants have adequate information required for in vivo bioequivalence studies, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons. Historically, there were two situations in which two listed drugs that had been shown to be bioequivalent to each other had both been identified by the symbol “+” in the Orange Book. The first situation was when the in vivo determination of bioequivalence is self-evident and a waiver of any in vivo bioequivalence may be granted. The second situation was when the bioequivalence of two listed products may be determined through in vitro methodology. If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an in vivo bioequivalence study submit a controlled correspondence to the Office of Generic Drugs. |
2楼2017-02-10 14:39:16
小朋友681
木虫 (正式写手)
- 应助: 1 (幼儿园)
- 金币: 3370.3
- 散金: 60
- 红花: 3
- 帖子: 785
- 在线: 200小时
- 虫号: 553909
- 注册: 2008-05-05
- 性别: GG
- 专业: 有机合成
星海慧儿3楼2017-02-19 22:51:53
星海慧儿
荣誉版主 (职业作家)
木虫精灵
- DRDEPI: 17
- 应助: 849 (博后)
- 贵宾: 0.978
- 金币: 22119.4
- 散金: 3714
- 红花: 103
- 沙发: 5
- 帖子: 3828
- 在线: 803.1小时
- 虫号: 568253
- 注册: 2008-06-03
- 专业: 分析化学
- 管辖: 新药研发
4楼2017-02-19 23:37:15
星海慧儿
荣誉版主 (职业作家)
木虫精灵
- DRDEPI: 17
- 应助: 849 (博后)
- 贵宾: 0.978
- 金币: 22119.4
- 散金: 3714
- 红花: 103
- 沙发: 5
- 帖子: 3828
- 在线: 803.1小时
- 虫号: 568253
- 注册: 2008-06-03
- 专业: 分析化学
- 管辖: 新药研发
|
橙皮书里的我也看了，我的情况是:原研有3个规格，都是RLD，其中最大规格的同时也被定为了RS。我仿制的是小规格，那也就是说我仿制的是小规格的就选对应的小规格的RLD作参比就行？到时候做BE再选被定为RS的大规格？这样药学和BE不就脱节了吗？最起码我也得用大规格的参比先研究一下溶出，跟仿制的小规格的对比一下的吧？所以我觉得药学应该选对应规格的同时还行增加大规格的RS研究，然后BE用大规格的RS。请大侠指正。 发自小木虫Android客户端 |
5楼2017-02-19 23:47:07
6楼2017-03-09 16:51:03
7楼2017-07-03 14:18:58